Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry - Quiz - MDSpire

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • By

  • Marisa Iborra

  • Berta Caballol

  • Alejandro Garrido

  • José María Huguet

  • Francisco Mesonero

  • Ángel Ponferrada

  • Lara Arias García

  • Marta Maia Boscá Watts

  • Samuel J Fernández Prada

  • Eduard Brunet Mas

  • Ana Gutiérrez Casbas

  • Elena Cerrillo

  • Ingrid Ordás

  • Lucía Ruiz

  • Irene García de la Filia

  • Jaime Escobar Ortiz

  • Beatriz Sicilia

  • Elena Ricart

  • Eugeni Domènech

  • Pilar Nos

  • August 22, 2024

  • 0 min

Share

Original Source(s)

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • by Marisa Iborra, Berta Caballol, Alejandro Garrido, José María Huguet, Francisco Mesonero, Ángel Ponferrada, Lara Arias García, Marta Maia Boscá Watts, Samuel J Fernández Prada, Eduard Brunet Mas, Ana Gutiérrez Casbas, Elena Cerrillo, Ingrid Ordás, Lucía Ruiz, Irene García de la Filia, Jaime Escobar Ortiz, Beatriz Sicilia, Elena Ricart, Eugeni Domènech, Pilar Nos

  • August 22, 2024

Related Content

Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance